Literature DB >> 22302550

β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.

K M Rodrigue1, K M Kennedy, M D Devous, J R Rieck, A C Hebrank, R Diaz-Arrastia, D Mathews, D C Park.   

Abstract

OBJECTIVE: Several lines of evidence suggest that pathologic changes underlying Alzheimer disease (AD) begin years prior to the clinical expression of the disease, underscoring the need for studies of cognitively healthy adults to capture these early changes. The overall goal of the current study was to map the cortical distribution of β-amyloid (Aβ) in a healthy adult lifespan sample (aged 30-89), and to assess the relationship between elevated amyloid and cognitive performance across multiple domains.
METHODS: A total of 137 well-screened and cognitively normal adults underwent Aβ PET imaging with radiotracer (18)F-florbetapir. Aβ load was estimated from 8 cortical regions. Participants were genotyped for APOE and tested for processing speed, working memory, fluid reasoning, episodic memory, and verbal ability.
RESULTS: Aβ deposition is distributed differentially across the cortex and progresses at varying rates with age across cortical brain regions. A subset of cognitively normal adults aged 60 and over show markedly elevated deposition, and also had a higher rate of APOE ε4 (38%) than nonelevated adults (19%). Aβ burden was linked to poorer cognitive performance on measures of processing speed, working memory, and reasoning.
CONCLUSIONS: Even in a highly selected lifespan sample of adults, Aβ deposition is apparent in some adults and is influenced by APOE status. Greater amyloid burden was related to deleterious effects on cognition, suggesting that subtle cognitive changes accrue as amyloid progresses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302550      PMCID: PMC3280058          DOI: 10.1212/WNL.0b013e318245d295

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

2.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

Authors:  Christopher C Rowe; Kathryn A Ellis; Miroslava Rimajova; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; Jurgen Fripp; Henri Tochon-Danguy; Laurence Morandeau; Graeme O'Keefe; Roger Price; Parnesh Raniga; Peter Robins; Oscar Acosta; Nat Lenzo; Cassandra Szoeke; Olivier Salvado; Richard Head; Ralph Martins; Colin L Masters; David Ames; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2010-05-15       Impact factor: 4.673

3.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

4.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.

Authors:  S M Resnick; J Sojkova; Y Zhou; Y An; W Ye; D P Holt; R F Dannals; C A Mathis; W E Klunk; L Ferrucci; M A Kraut; D F Wong
Journal:  Neurology       Date:  2010-02-10       Impact factor: 9.910

5.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

Authors:  Martha Storandt; Mark A Mintun; Denise Head; John C Morris
Journal:  Arch Neurol       Date:  2009-12

Review 6.  Beta-amyloid deposition and the aging brain.

Authors:  Karen M Rodrigue; Kristen M Kennedy; Denise C Park
Journal:  Neuropsychol Rev       Date:  2009-11-12       Impact factor: 7.444

7.  Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.

Authors:  P Bourgeat; G Chételat; V L Villemagne; J Fripp; P Raniga; K Pike; O Acosta; C Szoeke; S Ourselin; D Ames; K A Ellis; R N Martins; C L Masters; C C Rowe; O Salvado
Journal:  Neurology       Date:  2010-01-12       Impact factor: 9.910

8.  Cognition, reserve, and amyloid deposition in normal aging.

Authors:  Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

9.  Disruption of functional connectivity in clinically normal older adults harboring amyloid burden.

Authors:  Trey Hedden; Koene R A Van Dijk; J Alex Becker; Angel Mehta; Reisa A Sperling; Keith A Johnson; Randy L Buckner
Journal:  J Neurosci       Date:  2009-10-07       Impact factor: 6.167

10.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Authors:  Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  191 in total

1.  The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory.

Authors:  Karen M Rodrigue; Ana M Daugherty; E Mark Haacke; Naftali Raz
Journal:  Cereb Cortex       Date:  2012-05-29       Impact factor: 5.357

2.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

3.  Fragmented Sleep and Cortical Thinning in Old Adults: Time to Wake Up?

Authors:  Michael W L Chee
Journal:  Sleep       Date:  2016-01-01       Impact factor: 5.849

Review 4.  (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.

Authors:  Robert E Becker; Nigel H Greig; Debomoy K Lahiri; Joseph Bledsoe; Sarah Majercik; Clive Ballard; Dag Aarsland; Lon S Schneider; Douglas Flanagan; Ramprakash Govindarajan; Mary Sano; Luigi Ferrucci; Dimitrios Kapogiannis
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

5.  The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal.

Authors:  Jenny R Rieck; Karen M Rodrigue; Kristen M Kennedy; Michael D Devous; Denise C Park
Journal:  Hum Brain Mapp       Date:  2015-04-02       Impact factor: 5.038

6.  Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2017-04-12       Impact factor: 2.035

Review 7.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

8.  Short-term repeat cognitive testing and its relationship to hippocampal volumes in older adults.

Authors:  Kevin Duff; Jeffrey S Anderson; Atul K Mallik; Kayla R Suhrie; Taylor J Atkinson; Bonnie C A Dalley; Sarah Shizuko Morimoto; John M Hoffman
Journal:  J Clin Neurosci       Date:  2018-08-22       Impact factor: 1.961

9.  Contribution of cerebrovascular health to the diagnosis of Alzheimer disease.

Authors:  Karen M Rodrigue
Journal:  JAMA Neurol       Date:  2013-04       Impact factor: 18.302

10.  White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?

Authors:  Frank A Provenzano; Jordan Muraskin; Giuseppe Tosto; Atul Narkhede; Ben T Wasserman; Erica Y Griffith; Vanessa A Guzman; Irene B Meier; Molly E Zimmerman; Adam M Brickman
Journal:  JAMA Neurol       Date:  2013-04       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.